Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

ADARx Pharmaceuticals

Tracked across 2 events · 12 articles · First seen Sep 21, 2026 · Last active Sep 22, 2026

Sentiment
18
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 30
Business
ADARx Pharmaceuticals, a San Diego-based developer of RNA-based drugs for rare immune, kidney, cardiovascular and neurological diseases, announced on September 21, 2026 that it is seeking a valuation of up to $1.74 billion in its…
Impact: The central entity of the event, seeking up to $1.74 billion valuation and $371.9 million in proceeds via a Nasdaq listing under ADRX. A successful IPO would fund late-stage trials of onvuzosiran and validate its RNA drug platform.
Sep 21, 2026 · 6 articles
2 5
Business
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the…
Impact: Launched its IPO roadshow the same day, part of the busy fall biotech listing slate.
Sep 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track ADARx Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.